Dorian Laslo

Dorian Laslo

Auto-generated profile, based on publicly available information

Dorian Laslo

Josip Juraj Strossmayer University of Osijek, Osijek, Croatia

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Turkish Journal of Emergency Medicine
Verified
Journal Article
Open access
VPVlatka Periša
Vlatka Periša
DLDorian Laslo
Dorian Laslo
LMLana Maričić
Lana Maričić
LZLada Zibar
Lada Zibar
This is the first report on a case of perindopril/amlodipine-induced thrombotic microangiopathy (TMA) syndrome. A 48-year-old female was admitted complaining of nettle rash all over the body, bloody urine, and weakness shortly after starting antihypertensive therapy with perindopril/amlodipine. Shortly thereafter, she developed pronounced hemiparesis, somnolence, and sensorimotor aphasia. Laboratory findings were compatible with microangiopathic hemolytic anemia and thrombocytopenia. She was diagnosed with TMA. Cessation of perindopril/amlodipine therapy and treatment with plasma exchange and systemic corticosteroids resulted in full recovery. Very seldom perindopril/amlodipine may cause hematologic abnormalities, probably through an immunological mechanism, but there were no reports of causing TMA so far. In our case, the symptoms began shortly after the start of perindopril/amlodipine use. The clinical course of TMA in the case was compatible with TMA related to an acute, immune-mediated drug reaction. The most important thing is to promptly recognize TMA and its induction by a drug because distinctive treatment and cessation of the suspected drug can prevent severe outcome, as it was avoided in our patient.

30 September 2025 in Periodicum Biologorum
Verified
Journal Article
Open access
PDF file
AHAnđela Horvat
Anđela Horvat
JJJanja Josić
Janja Josić
DLDorian Laslo
Dorian Laslo
MPMaša Hrelec Patrlj
Maša Hrelec Patrlj
Ignacija VlašićIgnacija Vlašić
Ignacija Vlašić
Ovarian cancer is one of the most common and deadliest tumors among women. Despite recent clinical advances, the combination of platinum-based chemotherapy and surgery remains the first-line therapeutic option. Due to frequent detection at an advanced stage and development of therapy resistance, the disease prognosis is often poor, and mortality rates remain high. Therefore, it is necessary to investigate new therapeutic approaches that would contribute to increased survival and higher life quality of ovarian cancer patients. One of these approaches is the use of the pro-oxidant effect of certain drugs that can disrupt the redox balance in tumor cells and lead to their death. Vitamin C (ascorbic acid or ascorbate) used in high concentrations suppresses cancer cell growth and metastasis. There are several mechanisms by which vitamin C exerts its antitumor function including pro-oxidant activity, epigenetic reprogramming and tumor environment oxygen sensing. The potential use of vitamin C in combinatorial therapies (as a support to standard therapies) should be reconsidered through more detailed mechanistic and clinical studies. Finding new therapeutic approaches would augment the available mechanisms in the fight against cancer leading to the increase in patient welfare and overall survival of cancer patients.